CoChat

Altering murine leukemia virus integration through disruption of the integrase and BET protein family interaction

Open access

The DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.

Abstract

We report alterations to the murine leukemia virus (MLV) integrase (IN) protein that successfully result in decreasing its integration frequency at transcription start sites and CpG islands, thereby reducing the potential for insertional activation. The host bromo and extraterminal (BET) proteins Brd2, 3 and 4 interact with the MLV IN protein primarily through the BET protein ET domain. Using solution NMR, protein interaction studies, and next generation sequencing, we show that the C-terminal tail peptide region of MLV IN is important for the interaction with BET proteins and that disruption of this interaction through truncation mutations affects the global targeting profile of MLV vectors. The use of the unstructured tails of gammaretroviral INs to direct association with complexes at active promoters parallels that used by histones and RNA polymerase II. Viruses bearing MLV IN C-terminal truncations can provide new avenues to improve the safety profile of gammaretroviral vectors for human gene therapy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/nar/gku175

Cites

52 of 52 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1. NMR analysis of MLV IN: Brd3 ET interaction. A. MLV IN CTD sequence is displayed with the following color codes: green indicates backbone amide resonance chemical shifts that were the same for IN CTD in the presence or absence of Brd3 ET at pH 8.0; red indicates backbone amide resonances that are observed in the presence of Brd3 ET, but solvent exchange broadened in the absence of complex formation, and/or amide resonances that exhibit frequency shifts upon complex formation; blue indicates backbone amide resonance assignments that could not be determined at pH 8.0 either in the presence or absence of the Brd3 ET domain. Residues for which HN amide assignments could not be determined in either free or ET-bound CTD at pH 8.0 include R337, H338, T340, K341, N342, R346, W347, A367, S385, S386, Q396, as well as proline residues P345, P350, P358, P380, P384, P398 and P408 which lack amide protons. B. Cα backbone trace, along with key structural features, of an ensemble of 20 conformers of MLV IN CTD from amino acids 329–408 (PDB ID 2M9U) is shown in this panel with the same color codes as described in panel A. C. Ribbon representation of a single MLV IN CTD conformer is shown within a transparent view of a surface space fill model. Color code is the same as in panel A with key structural features and specific amino-acid residues that show significant CSPs and/or reduced amide proton exchange broadening marked in red. All images were generated using PyMol (The PyMOL Molecular Graphics System, Version 1.2r3pre, Schrödinger, LLC.) D. NMR spectrum of the IN CTD–Brd3 ET complex. Overlay of [15N−1H]-HSQC spectra of 15N-enriched IN CTD construct IN329–408 at pH 8.0, 300 mM NaCl either with (blue) or without (red) unlabeled Brd3ET. The stoichiometric ratio of IN329–408 (1 mM) and Brd3 ET (2 mM) was 1:2 at the concentrations indicated. Backbone amide resonances that are not affected by complex formation are labeled with sequence-specific assignments in black; assigned amide resonances that are not observable due to solvent-exchange broadening in the absence of ET, but become observable upon complex formation, as well as resonances exhibiting significant CSPs upon complex formation are labeled in magenta. All amide peak resonances not observable due to solvent-exchange broadening in the absence of ET, but become observable upon complex formation are marked with black circles; some of these could not be unambiguously assigned at pH 8.0. The curved green arrows indicate the CSPs due to complex formation of the amide resonances assigned to residues L399, L403, A407 and the side-chain indole NHϵ resonance of W390. Tryptophan W347 and W369 NHϵ side chain indole resonances with significant proton exchange rate reduction due to complex formation are also indicated. Peak resonances labeled in green are assigned to the non-cleavable affinity tag.
Figure 1. NMR analysis of MLV IN: Brd3 ET interaction. A. MLV IN CTD sequence is displayed with the following color codes: green indicates backbone amide resonance chemical shifts that were the same for IN CTD in the presence or absence of Brd3 ET at pH 8.0; red indicates backbone amide resonances that are observed in the presence of Brd3 ET, but solvent exchange broadened in the absence of complex formation, and/or amide resonances that exhibit frequency shifts upon complex formation; blue indicates backbone amide resonance assignments that could not be determined at pH 8.0 either in the presence or absence of the Brd3 ET domain. Residues for which HN amide assignments could not be determined in either free or ET-bound CTD at pH 8.0 include R337, H338, T340, K341, N342, R346, W347, A367, S385, S386, Q396, as well as proline residues P345, P350, P358, P380, P384, P398 and P408 which lack amide protons. B. Cα backbone trace, along with key structural features, of an ensemble of 20 conformers of MLV IN CTD from amino acids 329–408 (PDB ID 2M9U) is shown in this panel with the same color codes as described in panel A. C. Ribbon representation of a single MLV IN CTD conformer is shown within a transparent view of a surface space fill model. Color code is the same as in panel A with key structural features and specific amino-acid residues that show significant CSPs and/or reduced amide proton exchange broadening marked in red. All images were generated using PyMol (The PyMOL Molecular Graphics System, Version 1.2r3pre, Schrödinger, LLC.) D. NMR spectrum of the IN CTD–Brd3 ET complex. Overlay of [15N−1H]-HSQC spectra of 15N-enriched IN CTD construct IN329–408 at pH 8.0, 300 mM NaCl either with (blue) or without (red) unlabeled Brd3ET. The stoichiometric ratio of IN329–408 (1 mM) and Brd3 ET (2 mM) was 1:2 at the concentrations indicated. Backbone amide resonances that are not affected by complex formation are labeled with sequence-specific assignments in black; assigned amide resonances that are not observable due to solvent-exchange broadening in the absence of ET, but become observable upon complex formation, as well as resonances exhibiting significant CSPs upon complex formation are labeled in magenta. All amide peak resonances not observable due to solvent-exchange broadening in the absence of ET, but become observable upon complex formation are marked with black circles; some of these could not be unambiguously assigned at pH 8.0. The curved green arrows indicate the CSPs due to complex formation of the amide resonances assigned to residues L399, L403, A407 and the side-chain indole NHϵ resonance of W390. Tryptophan W347 and W369 NHϵ side chain indole resonances with significant proton exchange rate reduction due to complex formation are also indicated. Peak resonances labeled in green are assigned to the non-cleavable affinity tag.CC BY-NC · PubMed Central
Figure 2. MLV IN interacts with the BET family through the IN TP. A. Rotational correlation time measurements. Plot of rotational correlation time (τc) computed from 15N T1/T2 relaxation rate measurements versus molecular weight. Known monomeric protein standards are indicated in red. Data for the three IN CTD constructs (IN329–408, IN329–385 XN and IN329–385) are indicated in blue (individually) and green (in the presence of the Brd3 ET domain). The molar ratio of the IN CTD constructs and Brd3 ET proteins was 1:1 at 100 μM. Plots of the 15N T1 and T2 nuclear relaxation data for each sample are presented in Supplementary Figure S2. B. Interaction of MLV IN TP with Brd4. GST pull-down experiments performed with WT GST-MLV IN1–408 and IN ΔC construct GST-MLV IN1–385 with Brd41–720. Coomassie stain of SDS/PAG of GST pull-down products. Components of individual reactions are indicated as well as 10% of the purified Brd41–720 input sample. The predicted molecular of the GST-MLV IN1–408 fusion protein is 69 kDa. Positions of molecular weight standards are indicated on the left.
Figure 2. MLV IN interacts with the BET family through the IN TP. A. Rotational correlation time measurements. Plot of rotational correlation time (τc) computed from 15N T1/T2 relaxation rate measurements versus molecular weight. Known monomeric protein standards are indicated in red. Data for the three IN CTD constructs (IN329–408, IN329–385 XN and IN329–385) are indicated in blue (individually) and green (in the presence of the Brd3 ET domain). The molar ratio of the IN CTD constructs and Brd3 ET proteins was 1:1 at 100 μM. Plots of the 15N T1 and T2 nuclear relaxation data for each sample are presented in Supplementary Figure S2. B. Interaction of MLV IN TP with Brd4. GST pull-down experiments performed with WT GST-MLV IN1–408 and IN ΔC construct GST-MLV IN1–385 with Brd41–720. Coomassie stain of SDS/PAG of GST pull-down products. Components of individual reactions are indicated as well as 10% of the purified Brd41–720 input sample. The predicted molecular of the GST-MLV IN1–408 fusion protein is 69 kDa. Positions of molecular weight standards are indicated on the left.CC BY-NC · PubMed Central
Figure 3. Mutating the consensus TP sequence inhibits interaction of MLV IN CTD with Brd3 ET. A. The 24-residue WT TP sequence is displayed on top and the mutant TP sequence is displayed on bottom. Underlined residues indicate amino-acid residues mutated to alanine. B. Comparison of [15N-1H]-HSQC spectra of the complex formed between 15N-enriched IN CTD (construct IN329–408) and unlabeled Brd3 ET in the presence of the WT TP (blue) and the free 15N-enriched IN CTD (construct IN329–408) spectra (red; same as Supplementary Figure S1B). The stoichiometric ratio of IN329–408 (200 μM) and Brd3 ET (200 μM) was 1:1 and the peptide was added at 3-fold molar excess (600 μM). Under these conditions, the WT TP disrupts the complex by binding to the ET domain, resulting in a spectrum for CTD that is different from that of the complex, but essentially identical to that of free IN CTD. C. Comparison of [15N-1H]-HSQC spectra of 15N-enriched IN CTD (construct IN329–408) and unlabeled Brd3 ET in the presence (red) or absence (blue) of the mutant TP. The stoichiometric ratio of IN329–408 (200 μM) and Brd3 ET (200 μM) was 1:1 and the mutant peptide was added at 3-fold excess (600 μM). The mutant TP does not disrupt the complex, and the spectrum is not changed when the peptide is added. In both panels, backbone amide resonances are labeled in black and peak resonances labeled in magenta are assigned to the non-cleavable affinity tag. Buffer conditions are as follows—buffer 1: 25 mM sodium phosphate pH 8.0, 300 mM NaCl, 50 mM potassium glutamate, 5 mM 2-mercaptoethanol. Buffer 2: 25 mM sodium phosphate pH 8.0, 360 mM NaCl, 60 mM potassium glutamate, 6 mM 2-mercaptoethanol.
Figure 3. Mutating the consensus TP sequence inhibits interaction of MLV IN CTD with Brd3 ET. A. The 24-residue WT TP sequence is displayed on top and the mutant TP sequence is displayed on bottom. Underlined residues indicate amino-acid residues mutated to alanine. B. Comparison of [15N-1H]-HSQC spectra of the complex formed between 15N-enriched IN CTD (construct IN329–408) and unlabeled Brd3 ET in the presence of the WT TP (blue) and the free 15N-enriched IN CTD (construct IN329–408) spectra (red; same as Supplementary Figure S1B). The stoichiometric ratio of IN329–408 (200 μM) and Brd3 ET (200 μM) was 1:1 and the peptide was added at 3-fold molar excess (600 μM). Under these conditions, the WT TP disrupts the complex by binding to the ET domain, resulting in a spectrum for CTD that is different from that of the complex, but essentially identical to that of free IN CTD. C. Comparison of [15N-1H]-HSQC spectra of 15N-enriched IN CTD (construct IN329–408) and unlabeled Brd3 ET in the presence (red) or absence (blue) of the mutant TP. The stoichiometric ratio of IN329–408 (200 μM) and Brd3 ET (200 μM) was 1:1 and the mutant peptide was added at 3-fold excess (600 μM). The mutant TP does not disrupt the complex, and the spectrum is not changed when the peptide is added. In both panels, backbone amide resonances are labeled in black and peak resonances labeled in magenta are assigned to the non-cleavable affinity tag. Buffer conditions are as follows—buffer 1: 25 mM sodium phosphate pH 8.0, 300 mM NaCl, 50 mM potassium glutamate, 5 mM 2-mercaptoethanol. Buffer 2: 25 mM sodium phosphate pH 8.0, 360 mM NaCl, 60 mM potassium glutamate, 6 mM 2-mercaptoethanol.CC BY-NC · PubMed Central
Figure 4. MLV IN ΔC integrations lose association with TSS, CpG islands and known BET protein binding sites in 293 cells. A. Percentages of integration sites in 293 cells are plotted with respect to the distance from the annotated TSS compared to matched random controls (MRCs) (50). B. Percentages of integration sites are plotted with respect to the distance from the 5’ end of the nearest CpG islands compared to MRCs. C. Total BET binding sites in 293 cells. Integration sites were measured for its proximity to the 5’ boundary of known BET protein binding sites compared to MRCs. MRCs are selected randomly from the host genome respective to a restriction site and should have no relation to chromatin sites. D. BET protein chromatin binding sites that overlap with promoters as defined in LeRoy et al. ((19); additional file 8). Loss of association of the IN ΔC versus the WT IN within 100 bp of chromatin sites bound by BET proteins was statistically different with P < 0.001 for both the total BET sites and those localized to specific promoters, respectively. Square bracket denotes inclusion of the limit, while parenthesis denotes exclusion.
Figure 4. MLV IN ΔC integrations lose association with TSS, CpG islands and known BET protein binding sites in 293 cells. A. Percentages of integration sites in 293 cells are plotted with respect to the distance from the annotated TSS compared to matched random controls (MRCs) (50). B. Percentages of integration sites are plotted with respect to the distance from the 5’ end of the nearest CpG islands compared to MRCs. C. Total BET binding sites in 293 cells. Integration sites were measured for its proximity to the 5’ boundary of known BET protein binding sites compared to MRCs. MRCs are selected randomly from the host genome respective to a restriction site and should have no relation to chromatin sites. D. BET protein chromatin binding sites that overlap with promoters as defined in LeRoy et al. ((19); additional file 8). Loss of association of the IN ΔC versus the WT IN within 100 bp of chromatin sites bound by BET proteins was statistically different with P < 0.001 for both the total BET sites and those localized to specific promoters, respectively. Square bracket denotes inclusion of the limit, while parenthesis denotes exclusion.CC BY-NC · PubMed Central
Figure 5. Model for MLV integration. A. Assembly of BET proteins on acetylated histone tail (blue) in the presence of additional host factors and RNA Pol II (together marked as X) to TSS. MLV IN interacts with the ET domain of BET proteins through the IN TP (red) resulting in a preponderance of integrations near TSS. B. Loss of MLV IN TP results in loss of association with BET proteins and results in decreased targeting to BET binding sites and TSS.
Figure 5. Model for MLV integration. A. Assembly of BET proteins on acetylated histone tail (blue) in the presence of additional host factors and RNA Pol II (together marked as X) to TSS. MLV IN interacts with the ET domain of BET proteins through the IN TP (red) resulting in a preponderance of integrations near TSS. B. Loss of MLV IN TP results in loss of association with BET proteins and results in decreased targeting to BET binding sites and TSS.CC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 52 references

Cited by

See all 77

Metadata

Authors
Aiyer, S., Swapna, G. V. T., Malani, N., Aramini, J. M., Schneider, W. M., Plumb, M. R., Ghanem, M., Larue, R. C., Sharma, A., Studamire, B., Kvaratskhelia, M., Bushman, F. D., Montelione, G. T., & Roth, M. J.
Affiliations
  • Rutgers, The State University of New Jersey (US)
  • University of Pennsylvania (US)
  • The Ohio State University (US)
  • Brooklyn College (US)
Corresponding author
  • Montelione, Gaetano T.
  • Roth, Monica J.
Venue
Nucleic Acids Research
Published
2014-03-12
Volume
42
Issue
9
Pages
5917-5928
ISSN
  • 0305-1048 (ISSN-L)
  • 1362-4962
OpenAlex
W2128712095
Cited by
72
References
51
Citations by year
2026: 2 · 2025: 1 · 2024: 6 · 2023: 9 · 2022: 5 · 2021: 5 · 2020: 3 · 2019: 4 · 2018: 9 · 2017: 5 · 2016: 10 · 2015: 7 · 2014: 6
FWCI
6.11
Type
journal article
Language
en
Open access
Locations
  • Nucleic Acids Research (publishedVersion, cc-by-nc)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • CUNY Academic Works (City University of New York) (submittedVersion, cc-by-nc)
Funders
  • National Institutes of Health (GM094597, AI062520)
  • U.S. Public Health Service (PSCOOC-40-199)
  • National Institute of General Medical Sciences (R01GM070837, GM070837, GM088808, R01GM088808, GM094597, U54GM094597, SC2GM088095)
  • National Institute of Allergy and Infectious Diseases (AI062520, R21AI109522, AI052845, R01AI062520, R01AI052845, P30AI045008)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › CRISPR and Genetic Engineering
  • Health Sciences › Medicine › Oncology › CAR-T cell therapy research
Keywords
murine leukemia virus, integrase, BET proteins, BRD2, BRD3, BRD4, C-terminal tail, CpG islands, transcription start sites, gammaretroviral vectors, gene therapy safety, truncating mutations, vector targeting
MeSH terms
Bromodomain Containing Proteins, Amino Acid Sequence, Binding Sites, Humans, Models, Molecular, Molecular Sequence Data, Leukemia Virus, Murine, Protein Binding, Transcription Factors, Viral Proteins, RNA-Binding Proteins, Virus Integration, Sequence Deletion, Sequence Analysis, DNA, CpG Islands, Integrases, Nuclear Magnetic Resonance, Biomolecular, Transcription Initiation Site, Protein Interaction Domains and Motifs, HEK293 Cells, High-Throughput Nucleotide Sequencing

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Altering murine leukemia virus integration through disruption of the integrase and BET protein family interaction. https://app.cochat.ai/papers/10.1093/nar/gku175
The paper
Aiyer, S., Swapna, G. V. T., Malani, N., Aramini, J. M., Schneider, W. M., Plumb, M. R., Ghanem, M., Larue, R. C., Sharma, A., Studamire, B., Kvaratskhelia, M., Bushman, F. D., Montelione, G. T., & Roth, M. J. (2014). Altering murine leukemia virus integration through disruption of the integrase and BET protein family interaction. Nucleic Acids Research. https://doi.org/10.1093/nar/gku175

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.